联康生物科技集团有限公司（股票代码：00690）于香港联合交易所有限公司主板上市。根据最新公告，董事会建议寻求股东批准一项股份购回授权，最多回购相当于公司于相关决议案获股东大会通过当日已发行股份总数10%的股份。公告显示，截至决议案通过当日，公司已发行股份数约为5,971,228,147股，代表最多可回购约597,122,814股。
公告提到，此次购回资金将依法自公司合法可动用的资金来源支出，相关程序符合开曼群岛公司法及香港上市规则等法律法规。董事会认为，股份购回将有助于提升整体股东回报，并符合公司及股东的整体最佳利益。根据公告提供的最近月份股价区间，联康生物科技集团股价曾在0.055港元至0.168港元之间波动。
该购回授权尚待股东大会审议通过，相关细节则以公司正式公告为准。董事会同时提醒，若决议案获通过，具体执行时间与买回股份数量将视市况与公司资金状况而定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.